Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether pregnenolone will demonstrate significant
improvements in cognitive functioning and negative symptoms compared to patients receiving
placebo.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Research Foundation, Singapore
Collaborators:
Duke University National University, Singapore Singapore Clinical Research Institute